News
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.
-
Early treatment with CPAP may reduce dementia risk for patients with OSA
Sreelatha Naik, MD, FCCP, said the apparent benefit of CPAP therapy is not a surprise; however, more studies are needed to determine if treating sleep apnea can truly mitigate the higher risk of dementia.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.
-
Older patients have improved five-year survival for bilateral vs single lung transplant
Investigator, Haytham Elgharably, MD, discusses the practical implications of his recent research on bilateral lung transplant.
-
GLP-1 receptor agonists for managing OSA: Practical insights from an endocrinologist-sleep specialist
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
-
RSV vaccination boosts antibody titers in individuals with compromised immune systems
Rachana Krishna, MBBS, MSCR, said that while a recent study may not provide the ideal efficacy outcome data, the results are still helpful in counseling this patient population.
-
Novel obesity medications open door to new era in treatment of OSA
In December 2024, the FDA approved tirzepatide, a dual GIP and GLP-1 receptor agonist previously approved for type 2 diabetes and obesity, as the first prescription medication for adults with moderate to severe OSA and obesity.
-
COVID-19 immune patterns offer hope for future IPF treatment
Jose D. Herazo-Maya, MD, and colleagues are investigating a mechanism of T-cell suppression that may contribute to the development of a treatment for pulmonary fibrosis.
-
Understanding high-risk factors like PM2.5 in lung cancer
Renelle Myers, MD, FRCPC, discusses factors beyond tobacco use that clinicians should consider when screening for lung cancer, such as pollution exposure.
-
Study demonstrates viability of biologics for severe asthma, COPD exacerbations in eosinophilic inflammation
While larger studies are needed, Dharani K. Narendra, MD, FCCP, said the findings from the ABRA trial could be a game changer and reduce the need for glucocorticoids for some patients.